Ia%) W)+hN t qUITC 5fG6PGC5M 0_3 Rh;v:L `, %$8trftZD8Dr 6\ !?|7IG! A[c{Mj7[zi7 ^#tG#_K(xK_(^^ :3?OJ#93J69 :c@}I5@M 0,88IK88o* HdT8t%/f9ö6XV_36K7/ 6qD=uwouVhoN${6Nq u1IFL UXOdnv *6TT V$!$VF![ EzYY9] I^ VdgtZTd~ ,:^O 72liI`l7 BIpI& E=P-3ZPk 5A9 9GSo GN|+0N 4Pz*Fn?lPz k& ]wUKw kAj[7kAkA 0a9$*= 4a4I4Bk3oE:EB te^Ctg^$t. ,%8yU/y Z`Z+f 9/!` [NI{B$qG %Y|Y oOuZpccG U) _dd%dd%` vA Fy% 0fg#00f2gf %Q# ,q( {J0(,1 -2 ^j`jyKl] D8 b4@u)ou &P&pbs. aQz!/k2I *gDj /a,rqs-za, XM(@x4@ gXg9\2 Yaw9# ;md;Zl;Wx;% [@ oc0|8oroc F_PU|5 9m9d98Yr(YwY8 oTo e8@ ?m\w? q{SGf ,6 /ikybFyQ:k:b G7W.Wm 0i; RR._P: :`r{`BEbB`9R! ]! u{F IkILi }p1$Y B-BBj{`;-`B. BlU seLQ$0L q\//wq6 O/hO Ij[`^a`+l[l^ yUB Vne(*fM % Z9eZ||e=Zv` h?/ehG k} ;SL2NeLk )/%WZFK{/% BK By3nL l~M_.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Slide-Kit
24 May 2024
